A detailed history of Efg Asset Management (North America) Corp. transactions in Argenx Se stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 14,084 shares of ARGX stock, worth $8.79 Million. This represents 1.31% of its overall portfolio holdings.

Number of Shares
14,084
Previous 14,506 2.91%
Holding current value
$8.79 Million
Previous $6.24 Million 22.44%
% of portfolio
1.31%
Previous 1.1%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$434.22 - $551.9 $183,240 - $232,901
-422 Reduced 2.91%
14,084 $7.64 Million
Q2 2024

Jul 25, 2024

BUY
$356.01 - $451.55 $1.35 Million - $1.71 Million
3,786 Added 35.32%
14,506 $6.24 Million
Q1 2024

May 13, 2024

BUY
$356.95 - $413.29 $747,810 - $865,842
2,095 Added 24.29%
10,720 $4.22 Million
Q4 2023

Feb 08, 2024

SELL
$338.91 - $506.01 $504,975 - $753,954
-1,490 Reduced 14.73%
8,625 $3.28 Million
Q3 2023

Nov 02, 2023

SELL
$369.35 - $548.43 $513,027 - $761,769
-1,389 Reduced 12.07%
10,115 $4.97 Million
Q2 2023

Jul 28, 2023

SELL
$360.14 - $422.58 $675,982 - $793,182
-1,877 Reduced 14.03%
11,504 $4.48 Million
Q1 2023

Apr 27, 2023

SELL
$334.23 - $403.65 $715,586 - $864,214
-2,141 Reduced 13.79%
13,381 $4.99 Million
Q4 2022

Feb 03, 2023

SELL
$342.17 - $402.31 $535,838 - $630,017
-1,566 Reduced 9.16%
15,522 $5.88 Million
Q3 2022

Oct 28, 2022

SELL
$343.2 - $395.75 $527,155 - $607,872
-1,536 Reduced 8.25%
17,088 $6.03 Million
Q2 2022

Aug 04, 2022

SELL
$269.58 - $378.88 $679,611 - $955,156
-2,521 Reduced 11.92%
18,624 $7.06 Million
Q1 2022

Apr 26, 2022

BUY
$254.45 - $351.06 $5,089 - $7,021
20 Added 0.09%
21,145 $6.66 Million
Q4 2021

Feb 18, 2022

BUY
$272.01 - $353.03 $5.75 Million - $7.46 Million
21,125 New
21,125 $7.4 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.